WildonRFarwellMDMPH

Hospital Medicine/Hospitalist

Chief Medical Officer, Dyne Therapeutics

Dr. Farwell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

TOM: Testosterone in Older Men With Sarcopenia Start of enrollment: 2005 Jan 01
Terminated
Phase 4

PubMed

6 citations
Identifying Biomarkers of Spinal Muscular Atrophy for Further Development.
Jacqueline Glascock, Basil T Darras, Thomas O Crawford, Charlotte J Sumner, Stephen J Kolb
Journal of Neuromuscular Diseases. 2023-01-01
Corrigendum to 'Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen': Neuromuscular Disorders 31 (2021) 310-318/doi: 10...
Drew MacCannell, Zdenek Berger, Lilly East, Eugenio Mercuri, Janbernd Kirschner
Neuromuscular Disorders. 2022-01-01
18 citations
Implications of circulating neurofilamentsfor spinal muscular atrophytreatment early in life: A case series.
Christiano R. R. Alves, Marco Petrillo, Rebecca Spellman, Reid Garner, Ren Zhang
Molecular Therapy. Methods & Clinical Development. 2021-12-10

Dyne Therapies Showing Benefit for MD Patients, Per Clinical Trial DataMay 21st, 2024
Genentech Gains Clinical Development Exec by Appointing Lilli Petruzzelli; Paul Sekhri Caps Eventful Week, Naming Sapna Srivastava CFO of eGenesisMarch 5th, 2021
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical OfficerMarch 4th, 2021
Join now to see all